siRNA targeting hypoxia-inducible factor 1

Details siRNA targeting hypoxia-inducible factor 1 siRNA targeting hypoxia-inducible factor 1

2009-08-04

2010-06-15

Bowman, Amy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C514S04400A

Reexamination Certificate

active

07737267

ABSTRACT:
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.

REFERENCES:
patent: 6001992 (1999-12-01), Ackermann
patent: 6111086 (2000-08-01), Scaringe
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6291642 (2001-09-01), Weinstein
patent: 6506559 (2003-01-01), Fire et al.
patent: 6566127 (2003-05-01), Pavco
patent: 6965025 (2005-11-01), Gaarde et al.
patent: 6994979 (2006-02-01), Reed
patent: 7022831 (2006-04-01), Reed
patent: 7022837 (2006-04-01), Harding
patent: 7157570 (2007-01-01), Yen
patent: 7507811 (2009-03-01), Khvorova
patent: 7511132 (2009-03-01), Khvorova
patent: 7514550 (2009-04-01), Khvorova
patent: 7521191 (2009-04-01), Khvorova
patent: 7541453 (2009-06-01), Khvorova
patent: 2002/0081578 (2002-06-01), Plowman et al.
patent: 2002/0086321 (2002-07-01), Craig
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0150945 (2002-10-01), Finney
patent: 2003/0087259 (2003-05-01), Clancy et al.
patent: 2003/0105051 (2003-06-01), McSwiggen
patent: 2003/0143732 (2003-07-01), Fosnaugh
patent: 2003/0157030 (2003-08-01), Davis et al.
patent: 2003/0228597 (2003-12-01), Cowsert
patent: 2004/0006365 (2004-01-01), Brady
patent: 2004/0029275 (2004-02-01), Brown et al.
patent: 2004/0054155 (2004-03-01), Woolf
patent: 2004/0063654 (2004-04-01), Davis et al.
patent: 2004/0077574 (2004-04-01), Klinghoffer
patent: 2004/0101857 (2004-05-01), Ward
patent: 2004/0180357 (2004-09-01), Reich
patent: 2004/0191818 (2004-09-01), O'Toole
patent: 2004/0192629 (2004-09-01), Xu et al.
patent: 2004/0204380 (2004-10-01), Ackerman
patent: 2004/0219671 (2004-11-01), McSwiggen
patent: 2004/0248296 (2004-12-01), Beresford
patent: 2004/0248299 (2004-12-01), Jayasena
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0048529 (2005-03-01), McSwiggen
patent: 2005/0107328 (2005-05-01), Wyatt
patent: 2005/0130181 (2005-06-01), McSwiggen
patent: 2005/0176025 (2005-08-01), McSwiggen
patent: 2005/0181382 (2005-08-01), Zamore
patent: 2005/0186586 (2005-08-01), Zamore
patent: 2005/0227935 (2005-10-01), McSwiggen
patent: 2005/0239731 (2005-10-01), McSwiggen
patent: 2005/0245475 (2005-11-01), Khvorova
patent: 2006/0286575 (2006-12-01), Farrell
patent: 2007/0031844 (2007-02-01), Khvorova
patent: 2007/0254850 (2007-11-01), Lieberman
patent: 2007/0275465 (2007-11-01), Woppmann
patent: 2007/0281901 (2007-12-01), Yanni
patent: WO9800532 (1998-01-01), None
patent: WO0020645 (2000-04-01), None
patent: WO0021559 (2000-12-01), None
patent: WO0076497 (2000-12-01), None
patent: WO0244321 (2002-06-01), None
patent: WO03035869 (2003-05-01), None
patent: WO03035870 (2003-05-01), None
patent: WO03070897 (2003-08-01), None
patent: WO03070969 (2003-08-01), None
patent: WO03646625 (2003-08-01), None
patent: WO03072704 (2003-09-01), None
patent: WO2004031237 (2004-04-01), None
patent: WO2004046324 (2004-06-01), None
patent: WO2004048511 (2004-06-01), None
patent: WO2004090105 (2004-10-01), None
patent: WO2005001043 (2005-01-01), None
patent: WO2005078095 (2005-08-01), None
patent: WO2005089224 (2005-09-01), None
patent: WO2005117991 (2005-12-01), None
patent: WO2006015389 (2006-02-01), None
patent: WO2006110813 (2006-10-01), None
Abeliovich, et al. (2000) Mice Lacking Alph-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System. Neuron v.25:239-52.
Amarzguioui, Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes (2000) vol. 29, No. 21, 4113-4124.
Amarzguioui M et al, Tolerance for mutations and chemical modifications in a siRNA Nucleic Acids Research vol. 31, No. 2, Jan. 15, 2003 pp. 589-595 , XP002270887 ISSN: 0305-1048.
Bass, B.L., (2001) The Short Answer, Nature V.411:428-29.
Betrand (2002) Comparison of Antisense Oligonucleotides and siRNAs in cell culture and in vivo, Biotechnical and Biophysicial Research Communication 296:1000-1004.
Boutla, Shot 5′-phosphorylated double-stranded RNAs induce RNA interference in Drosophila, 1776-1780 (Brief Communication) (2001).
Brown et al. (1997) Identification and cDNA Cloning of a Novel Mammalian C2 Domain-Containing Phosphoinositide 3-kinase, HsC2-PI3K. Biochemical and Biophysical Research Communications. 233, 537-544.
Brummelkarna et al. A System for Stable Expression of Short Intereferring RNAs in Mammalian Cells, Science vol. 296 pp. 550-553 (2002).
Cahill et al. (1999) Characterization of MAD2B and Other Mitotic Spindle Checkpoint Genes. Genomics. 58:181-187.
Caplen et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate systems, Proc. Natl. Acad. Sci USA vol. 98, pp. 9742-9747 (2001).
Caplen, dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for analysis of RNA interference, Jul. 11, 2000; Gene; 252(1-2):95-105.
Caplen, RNAi as a gene therapy approach. Expert Opin. Ther. 3(4):575-586. (2003).
Chalk, siRNA db: a database of siRNA sequences. Nucleic Acids Research. vol. 33 pp. D131-D134 (2004).
Chen et al. (2005) TSSK5, A Novel Member of the Testis-Specific Serine/Threonin Kinase Family, Phosphorylates CREB at Ser-122, and Stimulates the CRE-CREB Responsive Pathway. Biochemical and Biophysical Research Communications. 333: 742-749.
Cherry, Michael J. (1995) Computer Manipulation of DNA and Protein Sequences. Current Protocols in Molecular Biology. 7.7.1-7.7.23.
Chi, Genomewide view of gene silencing by small interfering RNAs. PNAS vol. 100, No. 11, pp. 6343-6346 (2003).
Chinault, Overlap Hybridization Screening: Isolation and Characterization of Overlapping DNA Framgments Surroungin the leu2 Gene on Yeast Chromosome III (1979), 5(2):111-26.
Daniel et al., Specific association of Type I with Ran GTPase in lipopolysacchardie-mediated differentiation, Oncogene 2001, vol. 20: 2618-2625.
Dodelet et al. (2000) Eph Receptors and Ephrin Ligands: embryogenesis to tumorigenesis. Oncogene 19:5614-5619.
Domin et al.(1997) Cloning of Human Phosphoinositide 3-Kinase with a C2 Domain that Displays Reduced Sensitivity to the Inhibitor Wortmannin. Biochem. J., v.325:139-47.
Dottori, et al. (1998) EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tract, Proc. Natl. Acad. Sci. vol. 95, pp. 13248-13253, Neurobiology.
Ekholm, et al.(2004) Deregulation of Cyclin E in Human Cells Interferes with Prereplication Complex Assembly. The Journal of Cell Biology. vol. 165, pp. 789-800.
Elbashir et al. (2001) Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells. Nature vol. 411, pp. 494-498.
Elbashir et al. (2002) Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs. Methods. 26:199-213.
Elbashir, Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melaongaster,The EMBO Journal v. 20(23): 6877-6888 (2001).
El Touny, et al. (2006) Identification of Both Myt-I and Wee-I as Necessary Mediators of the P2I-Independent Inactivation of the Cdc-2/Cyclin BI complex and Growth Inhibition of TRAMP Cancer Cells by Genistein. The Prostate, vol. 66:1542-1555.
European Patent Office, European Patent Application No. 03786798.3 Office Action dated Nov. 15, 2007.
Far, R-K, The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides (2003) Nucleic Acids Research. vol. 31, No. 15, pp. 4417-4424.
Feng, et al. (2003) Inhibiting the Expression of DNA Replication-Initiation Proteins Induces Apoptosis in Human Cancer Cells. Cancer Research, vol. 63, pp. 7356-7364.
Fox, et al. (1995) cDNA Cloning and Tissue Distribution of Five Human EPH-like Receptor Protein-tyrosine kinases, Oncogene; 10(5): 897-905.
Futami et al. (2002) Induction of Apoptosis in Hela Cells with siRNA Expression Vector Targeted Against BLC-2. Nucleic Acids Research Supplement No. 2:251-2.
Genbank Accession NM 001790 Oct.

Affiliated with

Also associated with

Rating

siRNA targeting hypoxia-inducible factor 1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with siRNA targeting hypoxia-inducible factor 1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and siRNA targeting hypoxia-inducible factor 1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4212119